Geneva, Switzerland, December 3, 2021 – AMAL Therapeutics announced today that the latest findings of its research team is on line on the Cancers website. Results show that the heterologous prime-boost combination with a protein vaccine and a viral vector vesicular stomatitis virus immunologically reshapes TC-1 cold tumor model by recruiting cross-presenting dendritic cells, and polarizing CD4+ T cells towards an antitumor Th1 phenotype within the tumor and tumor-draining lymph nodes. Additionally, this study also highlights the design of a multi-epitope vaccine for cancer immunotherapy as shown in the MC-38 inflamed tumor model.